PENGGUNAAN PENANDA BIOLOGIS ANGIOGENIK RASIO s-Flt1 DAN PIGF SEBAGAI PREDIKTOR PREEKLAMSIA
Article Sidebar
Main Article Content
Abstract
Preeclampsia is a leading cause of maternal death worldwide. Preeclampsia involves multi-organ and characterized by hypertension and proteinuria. One of the hypothesis pathogenesisin preeclampsia is placental insufficiency. Its causing imbalance between angiogenic and antiangiogenic factors in maternal circulation. This imbalance factors are responsible for systemic vasoconstriction. However, until now, there is no predictor for preeclampsiain high risk pregnancy. Therefore, this review briefly describes the recent studies about utility of biologic angiogenesis marker, such as s-Flt1 and PIGF as predictor in preeclampsia
Downloads
Article Details
Copyright (c) 2019 Yelvi Levani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4:97-104.
Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013;347:f6564.
Maynard S, Min J, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003:22(2):143-148.
Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51(4):970-975.
Harihana N, Shoemker A, Wagner S. Pathophysiology of preeclampsia. ClinPract 2016(13): 33-37.
Chaiworapongsa T, Romero J, Espinoza E, et al. Evidence supporting the role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J ObstetGynecol 2004;190(6):1541-1547.
Levine R, Maynard S, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
Woolcock J, Hennessy A, Xu B, et al. Soluble Flt1 as a diagnostic marker of preeclampsia. Australian and New Zealand Journal of Obstetrics and Gynaecology 2008; 48:64-70.
Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013 Nov 5;
(19):2121-31.
Excellence. NIfHaC. CG107 NICE Guideline: Hypertension in Pregnancy.2012.
Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Preeclampsia. Lancet. 2016 Mar 5; 387(10022):999-1011.
Hofmeyr GJ, Seuc AH, Betrán AP, Purnat TD, Ciganda A, et al. The effect of calcium supplementation on blood pressure in nonpregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. Pregnancy Hypertens. 2015 Oct; 5(4):273-9.
Churchill D, Duley L, Thornton JG, Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database SystRev. 2013 Jul 26; (7):CD003106.